Prolonged Partial Response to Osimertinib after Disease Progression to Rociletinib in Metastasic EGFR T790M-Positive Non-Small Cell Lung Cancer

J Thorac Oncol. 2018 May;13(5):e77-e79. doi: 10.1016/j.jtho.2017.12.015.
No abstract available

Publication types

  • Case Reports
  • Letter

MeSH terms

  • Acrylamides / therapeutic use*
  • Aged
  • Aniline Compounds
  • Carcinoma, Non-Small-Cell Lung / drug therapy*
  • Carcinoma, Non-Small-Cell Lung / enzymology
  • Carcinoma, Non-Small-Cell Lung / pathology
  • Disease Progression
  • ErbB Receptors / biosynthesis
  • Humans
  • Lung Neoplasms / drug therapy*
  • Lung Neoplasms / enzymology
  • Lung Neoplasms / pathology
  • Male
  • Neoplasm Metastasis
  • Piperazines / therapeutic use*
  • Pyrimidines / therapeutic use*

Substances

  • Acrylamides
  • Aniline Compounds
  • Piperazines
  • Pyrimidines
  • osimertinib
  • rociletinib
  • EGFR protein, human
  • ErbB Receptors